Medindia

X

Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler

by Vishnuprasad on  October 26, 2015 at 7:27 PM Drug News   - G J E 4
Glenmark Pharmaceuticals has entered into an agreement with Poland based Celon Pharma to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler in Europe used for treatment of lung diseases.
 Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler
Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler
Advertisement

Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development and licensing agreement with Celon Pharma SA to develop and market a generic version of GSK's Seretide Accuhaler product - fluticasone and salmeterol dry powder inhaler in Europe upon commercialisation, Glenmark said in a statement.

Advertisement
"As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania, among others," it added.

Celon, on the other hand, shall receive an upfront payment, followed by certain milestone payments during various stages of the product's development from Glenmark, including royalties on sales, Glenmark said.

The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension, it added.

Commenting on the development, Glenmark Pharmaceuticals Ltd Chairman & MD Glenn Saldanha said: "The deal reinforces Glenmark's growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe."

Seretide, marketed by GlaxoSmithKline, is among the top three pharmaceutical brands in Europe with sales of USD 2.24 billion as per IMS, Glenmark said.

"The common experiences of both companies in the area of manufacturing, commercialisation and distribution of inhaled drugs will translate into greater availability of combination therapy in a DPI inhaler in many European countries," Celon Pharma CEO Maciej Wieczorek said.

The fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease.

Glenmark Pharmaceuticals shares were trading 1.32 percent up at Rs 1,033.20 per scrip during afternoon session on the BSE.



Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All